rdcu.be/cqPaP @bloombergkimmel Nature Cancer Mark Yarchoan Aditya Mohan Soren Charmsaz @FertigLab Won Jin Ho Johns Hopkins Kimmel Cancer Center Celebrating my second cover of my tech career.

Super proud of our team on our latest- here we directly compare the TME of 4 HCC mouse models with varying anti-PD1 sensitivities- tagging twitter users Daniel Zabransky James Leatherman 🇵🇱🇭🇷🇩🇪👨‍🔬🧬⚾️🇺🇦 Soren Charmsaz Nicole Gross Luciane T Kagohara 🇧🇷🧬👩🏻‍🔬👩🏻‍💻 Dr. Elizabeth Jaffee Mark Yarchoan aasldpubs.onlinelibrary.wiley.com/doi/abs/10.100…

Great work from our team lead by Won Jin Ho & Daniel Zabransky profiling TME of murine #HCC models pub in #Hepatology ➡️Hepa 1-6: invalid ICI model, HLA mismatch w/ C57BL6 ➡️Hep53.4 & RIL175 - mod ICI responsive ➡️TIBx: ICI-resistant aasldpubs.onlinelibrary.wiley.com/doi/abs/10.100…

Very honored and grateful to receive this award from Harrington Discovery Institute! Excited to develop new immunotherapeutic strategies to treat #PancreaticCancer - there’s so much to do. If you are interested in joining our efforts, we have openings wjhlab.com

1/Excited to share our latest research led by Chester Kao & Soren Charmsaz , published in Journal of Clinical Investigation! ➡️We found that immune-related adverse events (irAEs) in patients receiving IO are linked to Th17 and Th2 signatures jci.org/articles/view/…

Really enjoyed leveraging latest workflow tricks. The ability to batch 30+ samples per run by live-cell barcoding for CyTOF enhanced the rigor of the analysis + Soren Charmsaz and Nicole Gross employed CytoNorm (Sofie Van Gassen) to further normalize the data across batches.

New #JITC article: Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade bit.ly/40rGDnR Soren Charmsaz Aanika Balaji Evan Lipson Dr. Elizabeth Jaffee Mark Yarchoan

1/ Excited to share our study (rdcu.be/eiAyr) published today in Nature Communications led by Chester Kao, Soren Charmsaz, and Hua-Ling Tsai evaluating age-related differences in immune responses in patients with cancer treated with immune checkpoint inhibitors (ICIs).